Why Dame June should stay on at the MHRA

Revolving doors are an easy way out.

In the summer of 2023, we expressed our doubts about the UK MHRA’s ability to carry out its role of pharmacovigilance in an impartial way. Specifically, the MHRA seemed unable to follow through with …